Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Alcon Q4 2025 Earnings Call - Launch Momentum from Unity and Tryptyr Powers 2026 Guidance
Alcon closed 2025 on clear product momentum, led by Unity equipment rollouts, PanOptix Pro adoption in the U.S., and an unexpectedly strong Tryptyr launch in dry eye. The quarter delivered $2.7 billio...
- Q4 sales of $2.7 billion, up 7% year over year, with full year free cash flow of $1.7 billion versus $1.6 billion in 2024.
- Surgical franchise delivered $1.5 billion in Q4, up 6%; implantables were $474 million, up 2%, while consumables were $794 million, up 5%.
- Equipment accelerated strongly, $277 million in Q4 and up 18% year over year, driven largely by Unity platform placements and the late-2025 launch of Unity CS.
- +16 more takeaways
Recursion Pharmaceuticals Q4 2025 Earnings Call - AI-enabled platform shows clinical proof in FAP, runway extended to early 2028
Recursion used the quarter to argue that its decade-long bet on an end-to-end AI platform is beginning to pay clinical and commercial dividends. The company reported a positive clinical proof of conce...
- Clinical proof of concept: REC-4881 (MEK1/2 inhibitor) delivered a positive Phase 2 POC in FAP with a median 43% polyp burden reduction at 4 mg QD and a 75% responder rate; durable reductions persisted after 3 months off treatment.
- Regulatory path: Recursion plans initial engagement with the FDA on a registrational path for REC-4881 in the first half of 2026; 18 and over cohort is already recruiting and dose optimization is underway.
- Partnership momentum: Recursion achieved its fifth milestone with Sanofi, bringing total partner inflows to over $500 million cumulatively; Sanofi deal alone has paid $100 million upfront plus approximately $34 million in milestones to date.
- +11 more takeaways
Gladstone Land Corporation Q4 2025 Earnings Call - Lease Shift to Participation Rents and Water Assets Mask Near-Term AFFO Pressure
Gladstone Land spent 2025 balancing portfolio pruning, cash conservation, and an operational pivot on permanent crop leases. Management sold six farms for about $95 million and a $21 million aggregate...
- Sold six farms in 2025 for roughly $95 million and recognized about $21 million of aggregate gains, while still owning ~99,000 acres across 144 farms.
- Portfolio water assets concentrated in California: ~56,000 acre-feet of storage, which management translates to about 18 billion gallons; water availability and snowpack are currently favorable.
- Management shifted several permanent-crop leases from fixed base rent to higher crop-share participation, reducing fixed cash rent but creating timing and lippage in revenue and AFFO recognition.
- +11 more takeaways
BMO Financial Group Q1 2026 Earnings Call - ROE Rises to 13.1%; U.S. Optimization 90% Complete, Loan Growth Expected in H2 2026
BMO posted a strong start to 2026, driven by record pre-provision, pre-tax earnings of CAD 4.1 billion, adjusted EPS of CAD 3.48 (up 15% YoY), and underlying ROE of 13.1% (up 180 bps YoY). Management ...
- Adjusted EPS of CAD 3.48, up 15% year-over-year; reported EPS CAD 3.39 after a CAD 202 million severance charge (CAD 147 million after tax) that reduced EPS by CAD 0.21.
- Record pre-provision, pre-tax (PPPT) earnings of CAD 4.1 billion, driven by record revenue across operating segments.
- Underlying ROE reached 13.1%, up 180 basis points year-over-year and 130 basis points sequentially; ROTCE 17.1%, up 220 basis points.
- +11 more takeaways
UFP Technologies Q4 2025 Earnings Call - Contract Extension and Dominican Republic Capacity Push Give Visibility Despite AJR Labor Drag and Ransomware
UFP delivered a strong 2025 in top-line growth and cash generation, while navigating a messy mix of operational shocks. Revenue jumped 19.5% to $602.8 million and EPS rose 15.4% for the year, mileston...
- Full-year revenue rose 19.5% to $602.8 million, nearly tripling revenue since 2021, with operating income and EPS up ~435% and ~419% respectively over that four-year span.
- 2025 EPS grew 15.4% despite absorbing $6.3 million of labor inefficiencies at the AJR St. Charles, Illinois facility; that drag reduced full-year gross margin to 28.3% (would have been 29.3% absent the extra labor costs).
- AJR E-Verify disruption remains the principal near-term operational headwind, with a $1.2 million hit in Q4 versus roughly $3 million in Q3, management expects Q1 2026 impact to be smaller and to diminish each quarter thereafter.
- +14 more takeaways
ODDITY Q4 2025 Earnings Call - Major ad-platform algorithm change drove abnormal CPA spike, pressuring near-term growth but not the long-term strategy
ODDITY closed 2025 with record revenue and profitability, but the quarter’s flavor is caution. The company reported $810 million in 2025 net revenue (up 25%), adjusted EBITDA of $163 million (20.2% ma...
- 2025 results were strong: net revenue $810 million, up 25% year-over-year, with adjusted EBITDA $163 million and adjusted diluted EPS $2.21 for the year.
- Q4 2025 net revenue was $153 million, up 24% year-over-year; Q4 adjusted EBITDA was $13 million and adjusted diluted EPS was $0.20.
- Gross margin for 2025 expanded to 72.7% (up 30 basis points); Q4 gross margin was 70.5%, down 220 basis points year-over-year driven partly by product mix.
- +16 more takeaways
Alkermes plc Fourth Quarter 2025 Earnings Call - Alixorexton to Phase 3 as Avadel Buyout Recasts the Commercial Engine
Alkermes closed 2025 with a beefy commercial base and a strategic pivot into sleep medicine, sealing the Avadel acquisition and announcing plans to start phase 3 for alixorexton in narcolepsy this qua...
- Alkermes reported nearly $1.5 billion in total revenues for 2025, with proprietary product net sales of approximately $1.2 billion, driven by VIVITROL ($467.9M), ARISTADA ($370M), and Lybalvi ($346.7M).
- The company completed the Avadel acquisition in February 2026, using about $775 million of cash and drawing $1.525 billion of term loans due in 2031, positioning Alkermes to enter the commercial sleep medicine market.
- Alkermes expects 2026 total revenues of $1.73 billion to $1.84 billion, with proprietary product sales of $1.52 billion to $1.6 billion, reflecting roughly 10.5 months of Avadel contribution.
- +12 more takeaways
CLEAR Q4 2025 Earnings Call - CLEAR1 breakout and at least $440M Free Cash Flow guide
CLEAR closed fiscal 2025 with a clear pivot from investment to profitable scale. Q4 revenue rose 16.7% year over year to $240.8 million, bookings jumped 25.4% to $287.1 million, and Adjusted EBITDA ma...
- Q4 revenue grew 16.7% year over year to $240.8 million; Q4 Total Bookings rose 25.4% to $287.1 million.
- Full year 2025 revenue was $900.8 million, bookings $977.2 million, and Free Cash Flow totaled $343.1 million, ahead of guidance.
- Management delivered record profitability: Q4 Adjusted EBITDA of $79.9 million (33.2% margin) and full-year Adjusted EBITDA of $262.2 million (29.1% margin).
- +12 more takeaways
LivaNova PLC Q4 2025 Earnings Call - OSA PMA on Track and Epilepsy Reimbursement Jumpstarts Growth
LivaNova closed 2025 with double-digit top-line and EPS momentum, a stronger balance sheet, and a clear strategic pivot into obstructive sleep apnea. Management walked investors through steady cardiop...
- 2025 results: Double-digit revenue growth, fifth consecutive year of double-digit EPS growth, and third consecutive year of double-digit organic revenue growth.
- Q4 revenue was $361 million, up 9.5% on a constant currency and organic basis; favorable FX added about $9 million (roughly 3%).
- Cardiopulmonary Q4 revenue $207 million, full-year $785 million, up 13% year-over-year; HLM (heart-lung machine) growth remained strong (full-year mid-teens).
- +16 more takeaways
Golar LNG Limited Q4 2025 Earnings Call - On track to ~$800M EBITDA as Argentina FLNGs near start, commodity upside could dwarf base earnings
Golar spent Q4 2025 proving the plumbing of its FLNG strategy rather than selling the dream. Gimi is live and producing above contracted volumes, Hilli remains the benchmark for uptime, and Mark II co...
- Golar now owns three operational FLNG units and one Mark II conversion in progress, with a 20-year charter backlog for each of the main units.
- Gimi reached commercial operations in June 2025 and is producing above contracted volumes, invoicing a dayrate 3% above contractual levels in Q4 and showing potential for further overperformance seasonally.
- Hilli delivered 100% economic uptime in Q4, produced slightly above contracted volumes for the year, and will sail from Cameroon to Seatrium in Singapore after its current charter ends in July 2026 for life-extension and upgrades before redeployment to Argentina in mid-2027.
- +13 more takeaways